Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069167 | 0.77 | EPHX2 (0.70) | EPHX2EPHX1NPC1KMT2AHSD17B10 | |
| SCHEMBL11435229 | 0.70 | — | — | |
| SCHEMBL14653231 | 0.69 | SMN1; SMN2 (0.31) | — | |
| SCHEMBL19798754 | 0.69 | EPHX2 (0.82) | EPHX2EPHX1NPC1KMT2AHSD17B10 | |
| SCHEMBL12536864 | 0.66 | MAPT (0.40) | L3MBTL1 | |
| SCHEMBL4113338 | 0.66 | EPHX1 (0.96) | EPHX2EPHX1NPC1KMT2AHSD17B10 | |
| SCHEMBL15971518 | 0.66 | SMN1; SMN2 (0.37) | EPHX1KMT2AL3MBTL1 | |
| SCHEMBL7206413 | 0.65 | — | — | |
| SCHEMBL653169 | 0.65 | EPHX1 (1.00) | EPHX2EPHX1NPC1KMT2AHSD17B10 | |
| SCHEMBL3076327 | 0.64 | EPHX2 (0.55) | EPHX2EPHX1NPC1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233386-A1 | Compounds Which Have a Protective Activity with Respect to the Action of Toxins and of Viruses with an Intracellular Mode of Action | HAVCR2, MAVS, ANTXR2 | EPHX2 4690/4885EPHX1 4452/4885NPC1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.